Diary

  • Thu
    13
    Sep
    2018

    All dayManchester Airport

    This study day is being organised by Amgen.
    Elaine will deliver the morning session, covering:

    Part 1:
    The cellular and genetic make-up of acute lymphoblastic leukaemia (ALL)
    • A bit about B cells
    • Genetic drivers of ALL
    • Clonal evolution & intratumoural heterogeneity
    • The role of leukaemic stem cells

    Treating Philadelphia Chromosome Positive ALL
    • Bcr-Abl inhibitors
    • Other treatments

    Part 2:
    Licensed and novel treatments for ALL
    • Blinatumumab
    • Inotuzumab ozogamicin
    • CAR-modified T cells
    • Other treatments in trials

    Contact Elaine if you would like to know how to book a place.

    View the programme

  • Sun
    14
    Oct
    2018

    9:15 - 10:15Birmingham

    Elaine will be delivering a plenary session on Sunday morning.

    View the full programme:

    http://www.bopawebsite.org/sites/default/files/imce/BOPA1803-Agenda-2018.pdf

  • Tue
    04
    Dec
    2018

    Royal Marsden Hospital, London

    Description: 1-day course covering a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. Treatments described include: growth factor receptor inhibitors, kinase inhibitors, monoclonal antibodies, PARP inhibitors, ALK inhibitors, CDK inhibitors, immunotherapies.
    Level: Advanced
    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses
    Cost:
    £150
    To book, contact: conferenceteam@rmh.nhs.uk
    View an outline of the programme